Eurofins has successfully completed the acquisition of a majority stake in Bio-EC, Spincontrol and Genex, part of the Bio-EC / Spincontrol Group, as part of its ambitions to expand its global offering in the cosmetics and personal care sector. The acquisition adds ex vivo objectification and cosmetogenomics capabilities and strengthens the Eurofins Group's ability to perform ad-hoc clinical efficacy studies, emotional studies and image analysis.
By joining forces, Eurofins Cosmetics & Personal Care (C&PC) and Bio-EC, Spincontrol and Genex will leverage their respective expertise and capabilities to offer creative, unique and integrated solutions for cosmetics, dietary supplements and medical devices.
The French companies are headquartered in Paris and Tours, with three sites in France and Canada, and employ 58 people.
With 24 years of experience, Bio-EC brings innovative capabilities to Eurofins, with a strong position in ex vivo models and mechanisms and in vitro toxicology services, as well as new clinical facilities in Paris and unique expertise with its own in-house RAMAN. With the most sophisticated R&D capabilities and equipment, Bio-EC is involved in several research and innovation projects and channels its expertise to propose new models and methods every year.
As one of the industry's most experienced and influential companies in clinical efficacy studies, Spincontrol France and Spincontrol Canada support Eurofins Cosmetics & Personal Care's ambition to strengthen its portfolio and capture the value it brings to its customers. Well known in the market with 31 years of experience, Spincontrol will allow Eurofins C&PC to expand its existing clinical capabilities, ad hoc testing protocols and emotion studies, open up access to in-house image analysis and new imaging technologies, and bring its companies closer to local and regional customers in France and Canada.
Genex's expertise in cosmetogenomics will help Eurofins C&PC offer its clients a new way of monitoring gene expression to comprehensively identify product effects and reveal new targets and mechanisms.
